]>
IRCT20120109008665N14 IRCT 2021-08-31 Semnan University of Medical Sciences Comparison of the effectiveness of Turmeric and Ginger on the clinical manifestations and laboratory findings of patients with Covid-19 Comparison of the effectiveness of Turmeric and Ginger on the clinical manifestations and laboratory findings of patients with Covid-19 2021-09-16 anticipated 90 Complete https://irct.ir/trial/58418 interventional Randomization: Randomized, Blinding: Triple blinded, Placebo: Used, Assignment: Parallel, Purpose: Health service research, Randomization description: Assignment of samples (to two experimental groups and one control group) will be done by simple random method using sealed envelopes. In this method, the letter T represents the turmeric group, the letter G represents the ginger group and the letter C represents the control group, Blinding description: Participants are randomly assigned to groups using sealed envelopes containing the letters T, G, and C, each of which identifies intervention or control groups. Because drugs will be identified in similar, opaque, letter-only bottles, and patients will be treated on an outpatient basis at home, participants, the outcome assessor, and the data analyst are unaware of the allocation of individuals to experimentals and control groups. 3 COVID-19. Intervention 1: Intervention group: Group A (turmeric) receives 3 tablets of 500 mg of turmeric (curcuma) daily with standard treatment of Covid-19. The medicine will be given to the person by the therapeutic physician. Pills are taken by people before each meal.The pills are made by Dineh Pharmaceutical Company. Intervention 2: Intervention group: Group B (Vomigone) receives 3 tablets of 500 mg of ginger (Vomigone) daily with standard treatment of Covid-19. The medicine will be given to the person by the therapeutic physician. Pills are taken by people before each meal.The pills are made by Dineh Pharmaceutical Company. Intervention 3: Control group: Group C receives 3 tablets of 500 mg of placebo daily with standard treatment of Covid-19. The medicine will be given to the person by the therapeutic physician. Pills are taken by people before each meal.The pills are made by Dineh Pharmaceutical Company and contain compounds of polyvinyl pyrrolidone (PVP), microcrystalline cellulose (Avicel), starch and colorless. Undecided - It is not yet known if there will be a plan to make this available Justification or reason for indecision in sharing IPD is No more information
public Hassan Babamohamadi
Nursing and Midwifery Faculty, Semnan University of Medical Sciences, 5 Kilometers of Damghan Road, Semnan, Iran
Semnan Iran (Islamic Republic of) 3513138111 +98 23 3365 4192 babamohammady2007@gmail.com Semnan University of Medical Sciences scientific Hassan Babamohamadi
Nursing and Midwifery Faculty, Semnan University of Medical Sciences, 5 Kilometers of Damghan Road, Semnan, Iran
Semnan Iran (Islamic Republic of) 3513138111 +98 23 3365 4192 babamohammady2007@gmail.com Semnan University of Medical Sciences Iran (Islamic Republic of) Age 18 years or older Definitive diagnosis of Covid-19 disease (positive PCR, CT scan) Absence of chronic hepatitis Absence of cirrhosis Absence of cholestatic liver disease Absence of gallbladder inflammation Absence of peptic ulcers Lack of sensitivity to ginger Lack of sensitivity to turmeric Absence of women during pregnancy and lactation Do not take anti-inflammatory drugs such as Colchicine and Actemra 18 years no limit Both Reluctance to continue participating in research U07.1 COVID-19 Prevention Prevention Placebo Intervention group: Group A (turmeric) receives 3 tablets of 500 mg of turmeric (curcuma) daily with standard treatment of Covid-19. The medicine will be given to the person by the therapeutic physician. Pills are taken by people before each meal.The pills are made by Dineh Pharmaceutical Company. Intervention group: Group B (Vomigone) receives 3 tablets of 500 mg of ginger (Vomigone) daily with standard treatment of Covid-19. The medicine will be given to the person by the therapeutic physician. Pills are taken by people before each meal.The pills are made by Dineh Pharmaceutical Company. Control group: Group C receives 3 tablets of 500 mg of placebo daily with standard treatment of Covid-19. The medicine will be given to the person by the therapeutic physician. Pills are taken by people before each meal.The pills are made by Dineh Pharmaceutical Company and contain compounds of polyvinyl pyrrolidone (PVP), microcrystalline cellulose (Avicel), starch and colorless. Fever. Timepoint: From the beginning of the intervention until the fifth day. Method of measurement: Fever will be measured using a mercury thermometer. Cough. Timepoint: From the beginning of the intervention until the fifth day. Method of measurement: Severity of cough will be measured using the visual analog scale (VAS). Fatigue. Timepoint: From the beginning of the intervention until the fifth day. Method of measurement: Severity of fatigue will be measured using the visual analog scale (VAS). Sore throat. Timepoint: From the beginning of the intervention until the fifth day. Method of measurement: Severity of sore throat will be measured using the visual analog scale (VAS). Nasal congestion. Timepoint: From the beginning of the intervention until the fifth day. Method of measurement: Severity of nasal congestion will be measured using the visual analog scale (VAS). Diarrhea. Timepoint: From the beginning of the intervention until the fifth day. Method of measurement: The severity of diarrhea will be assessed by the number of times a day. Dyspnea. Timepoint: From the beginning of the intervention until the fifth day. Method of measurement: Severity of dyspnea will be measured using the visual analog scale (VAS). Complete blood count (CBC). Timepoint: At the beginning of the study (before the intervention) and at the end of the study (completion of the intervention). Method of measurement: Using the relevant laboratory kits. Erythrocyte sedimentation rate (ESR). Timepoint: At the beginning of the study (before the intervention) and at the end of the study (completion of the intervention). Method of measurement: Using the relevant laboratory kits. C-reactive protein (CRP). Timepoint: At the beginning of the study (before the intervention) and at the end of the study (completion of the intervention). Method of measurement: Using the relevant laboratory kits. Lactate dehydrogenase (LDH). Timepoint: At the beginning of the study (before the intervention) and at the end of the study (completion of the intervention). Method of measurement: Using the relevant laboratory kits. Semnan University of Medical Sciences Approved 2021-08-24 Semnan University of Medical Sciences Vice Chancellor of Research and Technology, Semnan University of Medical Sciences, Basidj Blv, Semnan, Iran Semnan Semnan Iran (Islamic Republic of)